Brought to you by 
Intellia, Novartis form five-year CRISPR/Cas9 collaboration
18 Jun 2021
Executive Summary
Over the next five years, Intellia Therapeutics Inc. and Novartis AG’s Novartis Institutes for BioMedical Research Inc. agreed to apply CRISPR/Cas9 gene editing and repair technologies ex vivo to chimeric antigen receptor T (CART) cells and hematopoietic stem cells (HSCs) for the treatment of cancers and hematological disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Intellia, Novartis form five-year CRISPR/Cas9 collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice